Version Française
Logo retour accueil

Last news

  • IntegraGen presents data on miR-31-3p biomarker at 2015 ELCC

    Results from a study exploring the role of the microRNA biomarker miR-31-3p in patients with advanced adenocarinoma of the lung were presented during the 2015 European Lung Cancer Conference (ELCC) held in Geneva, Switzerland.

    Read more

  • IntegraGen announces 2014 financial results

    IntegraGen today announced its financial results for the year ending December 31 2014. 

    Read more


IntegraGen's mission is to translate molecular research to clinical practice through the identification of novel genetic biomarkers and the subsequent commercialization of molecular diagnostic tests for autism and oncology based on these discoveries. The company also strives to be a leader in providing cutting edge genomic services to academic researchers and life sciences companies based on it's technological expertise and scientific know how.

Autism Oncology Services
Disclaimers - Mentions légales - Crédits